BiotechTube

LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)

Phase 1/2Completed
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diffuse Large B-cell Lymphoma

Conditions

Diffuse Large B-cell Lymphoma

Trial Timeline

Jan 1, 2011 → Feb 20, 2019

NCT ID
NCT02340936

About LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg)

LR-ESHAP (lenalidomide 5 mg) + LR-ESHAP (lenalidomide 10 mg) + LR-ESHAP (lenalidomide 15 mg) + LR-ESHAP (lenalidomide 20 mg) is a phase 1/2 stage product being developed by Thermo Fisher Scientific for Diffuse Large B-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02340936. Target conditions include Diffuse Large B-cell Lymphoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02340936Phase 1/2Completed

Competing Products

20 competing products in Diffuse Large B-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
IVA337 + PlaceboInventivaPhase 2
47
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)Eli LillyPhase 2
52
rituximabCelltrionPhase 1
33
YM155Astellas PharmaPhase 2
52
enzastaurin + gemcitabine + rituximab + oxaliplatinEli LillyPhase 2
52
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6Johnson & JohnsonPhase 2
52
VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + VincristineJohnson & JohnsonPhase 2
52
Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + GemcitabineAbbViePhase 3
77
ABBV-525AbbViePhase 1
33
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + EpcoritamabAbbViePhase 1/2
41
Copanlisib + VenetoclaxAbbViePhase 1/2
41
Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
77
Epcoritamab + LenalidomideAbbViePhase 2
52
Venetoclax + SelinexorAbbViePhase 1
33
EpcoritamabAbbViePhase 1
33
Loncastuximab Tesirine and EpcoritamabAbbViePhase 2
52
Epcoritamab + Investigator's Choice ChemotherapyAbbViePhase 3
77
bendamustine + navitoclax + rituximabAbbViePhase 2
52
EpcoritamabAbbViePhase 2
52
Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomideAbbViePhase 1/2
41

Other Products from Thermo Fisher Scientific

Tolvaptan + placeboPhase 3
76
zamtocabtagene autoleucel (MB-CART2019.1)Phase 2
51
BGP-15 100 mg QD + BGP-15 100 mg BID + Placebo BID + BGP-15 200 mg QD + BGP-15 200 mg BID + BGP-15 400 mg QDPhase 2
51
ShA9 Topical Gel + Hydrocortisone Ointment + Clobetasol Ointment + Fluocinonide Ointment + Placebo (Vehicle) Topical GelPhase 1
32
Olokizumab + Omeprazole + Caffeine + Warfarin+ Vitamin K + MidazolamPhase 1
32